Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer

International Journal of Biological Markers

Volumn 20, Issue 4, 2005, Pages 209-216

  Morote, Juan ^a   Esquena, S ^a   Abascal, J M ^a   Trilla, E ^a   Cecchini, L ^a   Raventos C X ^a   Orsola, A ^a   Planas, J ^a   Catalan R ^a   Reventos J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Androgen suppression; Metastatic prostate cancer; Prostate specific antigen nadir

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADRENAL SUPPRESSION; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE METASTASIS; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE REGRESSION; PREDICTION; PROGNOSIS; PROSTATE CANCER; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

EID: 30844451234     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080502000403     Document Type: Article

References (18)

1. Polascik C, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery - what we have learned and where we are going. J Urol 1999; 162: 293-306.
2. Zanett G, Trinchieri A, Del Nero A, et al. Prognostic significance of prostate specific antigen in endocrine treatment for prostate carcinoma. Eur Urol 1992; 21 (Suppl): 96-102.
3. Stamey TA, Kabalin JN, Ferrari M, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989; 141: 1088-90.
4. Arai Y, Yoshiki T, Yoshida O. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 1990; 144: 1415-9.
5. Matzkin H, Eber P, Todd B, van der Zwaag R, Soloway MS. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 1992; 70: 2302-9.
6. Miller JI, Ahmann FR, Drach GW, et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992; 147: 956-61.
7. Newling DW, Denis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer: analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer-Genitourinary Group Study 30853. Cancer 1993; 72: 3793-8.
8. Cooper EH, Armitage TG, Robinson MR, et al. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 1990; 66 (Suppl): S025-8.
9. Mulders PF, Fernández del Moral P, Theeuwes AG, et al. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol 1992; 21: 2-8.
10. Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Long-term efficacy and safety of changes of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol 1997; 158: 160-3.
11. Morote J, Vila J, López MA, de Torres JA, Soler-Roselló A. Value of prostate-specific antigen as prognostic factor of metastatic cancer of the prostate. Actas Urol Esp 1992; 16: 394-7.
12. Siddall JK, Hetherington JW, Cooper EH, et al. Biochemical monitoring of carcinoma of the prostate treated with an LH-RH analogue (Zoladex). Br J Urol 1986; 58: 676-81.
13. Daver A, Soret JY, Coblentz Y, et al. The usefulness of prostatic-specific antigen and prostatic acid phosphatase in clinical practice. Am J Clin Oncol 1998; 11 (Suppl): S53.
14. Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987; 138: 1181-4.
15. Benaim EA, Pace CM, Lam PO, Roehrborn CG. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 2002; 59: 73-8.
16. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen after hormone therapy for prostate cancer. J Urol 2002; 168: 995-1000.
17. Morote J, Trilla E, Esquena S, et al. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer 2004; 108: 877-81.
18. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202.